Jump to: Authorized Access | Attribution | Authorized Requests

Study Description
The implementation of targeted therapies for acute myeloid leukaemia (AML) has been challenging because of the complex mutational patterns within and across patients as well as a dearth of pharmacologic agents for most mutational events. This supplement data from the Beat AML program provides Adolescent and Young Adult (AYA) and pediatric tumor specimens not previously released. These data include exome and RNA level characterization as well as analyses of ex vivo drug sensitivity. Collectively, this data can be leveraged to address clinical, genomic, transcriptomic and functional analyses of the biology of leukemia in pediatric and AYA populations.
Authorized Access
Publicly Available Data (Public ftp)
Study Inclusion/Exclusion Criteria

Pediatric and AYA (< 40 years old) leukemia patients at diagnosis.

Selected Publications
Diseases/Traits Related to Study (MeSH terms)
Links to Related Resources
Authorized Data Access Requests
Study Attribution
  • Principal Investigator
    • Jeffrey Tyner, PhD. Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
  • Funding Sources
    • Leukemia and Lymphoma Society. Rye Brook, NY, USA.
    • 5P30CA069533. National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.